Remon’s first products, based on the Company’s core proprietary technology include:

RemonCHF – a device to monitor the hemodynamic status of patients with congestive heart failure (CHF)

RemonAAA – a device to monitor pressure, following an endograft procedure in AAA patients.

RemonCHF: Better Care for Congestive Heart Failure Patients
Congestive heart failure (CHF) is a chronic and progressive disease affecting 20 million people worldwide, in which the quantity of blood pumped by the heart (cardiac output) is insufficient to meet the body’s metabolic requirements. Management of CHF patients is a complex task that involves titration of several drugs, some of which may counteract with each other and trigger further compensatory responses. Practitioners aim to balance the patient’s hemodynamic status (e.g. blood circulation) in a state of compensation in order to minimize the progression of the disease, however currently they lack adequate information to decide on the most efficient treatment for each patient. The delicate balance of compensation is easily upset, even by seemingly benign factors, and a patient may plunge into a decompensation crisis, requiring immediate action to prevent a fatal outcome.

RemonCHF, is a monitoring system – deployed during a one-time, minimally-invasive catheter-based procedure – to provide unlimited, non-invasive frequent monitoring of patients in their own homes. The system will thus complete the therapy feedback loop, identifying high-risk patients for therapy adjustment before hospitalization is required, thereby resulting in considerable cost savings.

RemonAAA: Post-Operative Monitoring of Abdominal Aortic
Aneurysm Endo Grafts
An abdominal aortic aneurysm (AAA) is a ballooning of the abdominal aorta, a condition that affects 3 million people worldwide. Due to a progressive weakening of the vessel wall, AAAs gradually balloon, and if left untreated, the enlargement can lead to aortic rupture – fatal in nearly 80% of cases. If the diameter of the aneurysm exceeds 5.0 cm, surgical intervention is indicated, which has primarily been in the form of open abdominal surgery. In recent years a less-invasive procedure of inserting an endovascular stent graft has become more prevalent, and is expected to account for more than 65% of all AAA surgical procedures by 2003. Despite such advances, between 40-50% of patients who undergo the procedure develop a serious complication in which the aneurysmal sac is not completely isolated, leading to recurrent pressurization of the sac (endotension) and/or endoleaks. If undetected, this complication may lead to rupture of the sac and patient death. Post-operative monitoring is crucial, and as a result the FDA requires frequent monitoring (currently done by CT angiography scans) for patients who have undergone the procedure.

RemonAAA will allow physicians to directly and non-invasively monitor the most important parameters in assessing the risk of aneurysmal rupture.